CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections - Takeaways - MDSpire
From the Journals

CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

  • By

  • Andrea Surnit

  • May 13, 2026

  • 4 min

Share

  • 1

    Study analyzed outcomes of 520,405 patients with nonsevere COVID-

  • 2

    Antibiotic treatment was linked to higher risk of clinical deterioration and in-hospital mortality.

  • 3

    21% of antibiotic patients experienced the primary composite outcome.

  • 4

    There were no significant differences in adverse antibiotic events.

  • 5

    Elevated procalcitonin levels did not identify beneficial subgroups for antibiotic use.

  • 6

    Advocates for enhanced antibiotic stewardship strategies.

  • 7

    Study funded by the Agency for Healthcare Research and Quality.

Original Source(s)

CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections

  • by Andrea Surnit

  • May 13, 2026

Related Content

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.

How Social Contact Shapes Gut Microbes

Cooperative behavior linked to shared anaerobic gut bacteria

  • May 11, 2026

  • 2 min